• Acura Pharmaceuticals amended its loan schedule under a secured promissory note with Abuse Deterrent Pharma dated Nov. 10, 2022.
• The schedule expands aggregated principal to USD 11.09 million, up from USD 2.32 million under the original note.
• It adds USD 7.08 million of loans dated Dec. 22, 2022 through Dec. 31, 2025.
• Additional borrowings in 2026 total USD 1.7 million, including several USD 100,000 advances early in the year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acura Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-099200), on August 20, 2026, and is solely responsible for the information contained therein.